On November 16, 2023 Mongoose Bio, Inc., a private clinical-stage biopharmaceutical company pioneering nextgeneration precision T-cell based therapies targeting solid cancers reported that the Company received notice of a Product Development New Technologies Company Award of $10.6 Million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support clinical studies of its lead product candidate, MGB-001 (Press release, Mongoose Bio, NOV 16, 2023, View Source [SID1234647274]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CPRIT award would support a portion of the Company’s three-year global clinical program for the treatment of patients suffering from refractory gastric, esophageal, or non-small cell lung cancer (NSCLC). The planned study is designed to evaluate the benefit of MGB-001, an epigenetically reprogrammed autologous TCR-T cell therapy directed against a target that is both highly immunogenic and broadly expressed in many solid tumors. This therapy is built upon 17 years of pioneering work by founder Dr. Cassian Yee at his lab at the University of Texas MD Anderson Cancer Center (MDACC). Dr. Yee is a CPRIT Scholar.
"We are delighted that CPRIT and the Oversight Committee have approved this award to help us accelerate the clinical development of MGB-001 in various cancers," said Peter Hoang, Interim CEO of Mongoose Bio. "We are very grateful for this support from the State of Texas, which will enable us to accelerate our clinical programs for patients who have failed approved, front-line therapies in these difficult tumor indications. Many of our patients have few remaining treatment options, and we believe our proprietary epigenetic central memory T cell reprogramming has the potential to drive not only an enhanced response to T cell therapy, but also superior durability of those responses with a more persistent population of true central memory T cells. This technology has previously demonstrated very promising early clinical responses when used to enhance non-genetically modified T cells. The New Technologies Award from CPRIT will allow us to more fully evaluate MGB-001 in clinical trials."